Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.53 |
| ▸ | PLD2 | O14939 | 2/20 | 0.52 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875721 | 1.00 | SIGMAR1 (1.00) | SIGMAR1HTTACKR3PLD2PLD1 | |
| SCHEMBL4876861 | 0.89 | SIGMAR1 (1.00) | SIGMAR1PLD2PLD1MEN1KMT2A | |
| SCHEMBL4876867 | 0.89 | SIGMAR1 (1.00) | SIGMAR1PLD2PLD1MEN1KMT2A | |
| SCHEMBL4870315 | 0.80 | SIGMAR1 (1.00) | SIGMAR1PLD2PLD1MEN1KMT2A | |
| SCHEMBL4870310 | 0.80 | SIGMAR1 (1.00) | SIGMAR1PLD2PLD1MEN1KMT2A | |
| SCHEMBL4871963 | 0.79 | SIGMAR1 (0.79) | SIGMAR1PLD2PLD1 | |
| SCHEMBL4867118 | 0.79 | SIGMAR1 (0.97) | SIGMAR1PLD2PLD1MEN1KMT2A | |
| SCHEMBL4874862 | 0.75 | SIGMAR1 (1.00) | SIGMAR1CACNA1G | |
| SCHEMBL4874859 | 0.75 | SIGMAR1 (1.00) | SIGMAR1CACNA1G | |
| SCHEMBL30389381 | 0.74 | CCR3 (0.82) | SIGMAR1HTTPLD2PLD1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153917-A1 | Sigma Receptor Ligands | UCB PHARMA, S.A. (BE) | 2008-06-26 | — | — | US | claimed |
| EP-1797036-A1 | SIGMA RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006027252-A1 | SIGMA RECEPTOR LIGANDS | UCB PHARMA, SA (BE) | 2006-03-16 | — | — | WO | claimed |
| US-20080153917-A1 | Sigma Receptor Ligands | UCB PHARMA, S.A. (BE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153917-A1 | Sigma Receptor Ligands | SIGMAR1, TMEM97, OPRL1 | SIGMAR1 1/4885HTT 2766/4885ACKR3 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.